Sanjay Kaul, MD, FACC, FAHA Division of Cardiology Cedars-Sinai Medical Center Los Angeles, California
|
|
- Joshua Brendan Ball
- 6 years ago
- Views:
Transcription
1 Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay Kaul, MD, FACC, FAHA Division of Cardiology Cedars-Sinai Medical Center Los Angeles, California
2 The Laws of Diminishing Objectivity in the Interpretation of Evidence vehemence a evidence -1 vehemence a eminence 2 Peter McCulloch The Lancet, 2004;363;9004
3 Interleukin-1b as a Target for Atherosclerosis Biologic Basis for CANTOS and Beyond Libby P. JACC (October 31, 2017)
4 Modulation of IL-1b for Atheroprotection Neutralizing Antibody (Ilaris) Long half-life (4-8 weeks) Approved indications: - Cryopyrin-Associated Period Syndrome (CAPS) - Familial Cold Autoinflammatory Syndrome (FCAS) - Muckle-Wells Syndrome - Active systemic juvenile idiopathic arthritis - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) - Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) - Familial Mediterranean Fever (FMF). Not approved for gouty flare up because of safety concerns (2011) Cost per dose: $16K ($200K/y) Can Inflammation Reduction, in the Absence of Lipid Lowering, Reduce Cardiovascular Event Rates? Ridker PM. Circ Res 2016;118:
5 Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) Residual Inflammatory Risk (hscrp > 2 mg/l) N = 10, Countries April June Primary Events Randomized Canakinumab 50 mg SC q 3 months Randomized Canakinumab 150 mg SC q 3 months Randomized Canakinumab 300 mg SC q 3 months Randomized Placebo SC q 3 months Primary Endpoint: Nonfatal MI, Nonfatal Stroke, Cardiovascular Death (MACE) Secondary Endpoint: MACE plus Unstable Angina Requiring Urgent Revascularization (MACE+) Additional Adjudicated Endpoints: Cancer, Infection Ridker PM et al. N Engl J Med. 2017;377:
6 CANTOS - Baseline Clinical Characteristics Canakinumab SC q 3 months Characteristic 50 mg 150 mg 300 mg Placebo (N=2170) (N=2284) (N=2263) (N=3347) Age (years) Female (%) Current smoker (%) Diabetes (%) Lipid lowering therapy (%) Renin-angiotensin inhibitors (%) Prior Revascularization (%) LDL cholesterol (mg/dl) HDL cholesterol (mg/dl) Triglycerides (mg/dl) hscrp (mg/l) Ridker PM et al. N Engl J Med. 2017;377:
7 TG Percent Change from Baseline (median) HDLC LDLC hscrp CANTOS:Effects on Inflammatory Biomarkers & Lipids (48m) Placebo SC q 3 mth Canakinumab 50mg SC q 3 m (D = - 26%) Canakinumab 150mg SC q 3 m (D = - 37%) Canakinumab 300mg SC q 3 m (D = - 41%) Months Placebo Canakinumab 50 Canakinumab 150 Canakinumab 300 Ridker PM et al. N Engl J Med. 2017;377:
8 Cumulative Incidence (%) Cumulative Incidence (%) CANTOS Trial Primary Cardiovascular Endpoints MACE Placebo SC q 3 months Canakinumab 150/300 mg SC q 3 months MACE - Plus HR %CI P = HR %CI P = Follow-up Years Follow-up Years Ridker PM et al. N Engl J Med. 2017;377:
9 CANTOS Primary Clinical Outcome Effects Dose Response Endpoint Primary Endpoint IR (per 100 PY) HR 95%CI P value Secondary Endpoint IR (per 100PY) HR 95%CI P value Placebo (N=3347) (referent) (referent) (referent) (referent) *Statistically significant adjusted for multiplicity Canakinumab SC q 3 months 50 mg (N=2170) ( ) ( ) mg (N=2284) ( ) 0.021* ( ) 0.005* Ridker PM et al. N Engl J Med. 2017;377: mg (N=2263) ( ) ( ) Only 150 mg dose met multiplicity-adjusted PEP & SEP P-trend
10 CANTOS Components of PEP Canakinumab SC q 3 months(hr) Endpoint Placebo 50 mg 150 mg 300 mg P-trend (N=3347) (N=2170) (N=2284) (N=2263) Primary Secondary Myocardial Infarction Urgent Revascularization Any Coronary Revascularization <0.001 Stroke Cardiac Arrest CV Death All Cause Mortality No effect on stroke, CV death or all-cause mortality Ridker PM et al. N Engl J Med. 2017;377:
11 CANTOS Subgroup Analysis: Consistency of Treatment Group Women Men Age < 60 yrs Age > 60 yrs Diabetes No diabetes Non Smoker Smoker BMI < 30 kg/m2 BMI > 30 kg/m2 LDLC < 80 mg/dl LDLC > 80 mg/dl hscrp > 2 to <4 mg/l hscrp > 4 mg/l HDLC > 45 mg/dl HDLC < 45 mg/dl TG < 150 mg/dl TG > 150 mg/dl Overall MACE MACE Plus 0.5 Canakinumab Superior 1.0 Canakinumab Inferior Ridker PM et al. N Engl J Med. 2017;377: Canakinumab Superior 1.0 Canakinumab Inferior
12 CANTOS Safety Outcomes Canakinumab SC q 3 months Adverse event Placebo 50 mg 150 mg 300 mg P-trend (N=3347) (N=2170) (N=2284) (N=2263) Any SAE Leukopenia Any infection Fatal infection /0.02* Injection site reaction Any Malignancy Fatal Malignancy Arthritis Osteoarthritis Gout ALT > 3x normal * P-value for combined canakinumab doses vs placebo risk of leukopenia, thrombocytopenia, and fatal infection risk of fatal cancer, osteoarthritis and gout Ridker PM et al. N Engl J Med. 2017;377:
13 Evaluation of CANTOS Trial Deep Dive Benefit-risk balance of Canakinumab Robustness of outcomes Lack of low or normal hscrp group Totality of evidence Implications
14 Benefit Risk Balance of Canakinumab (CANTOS) 1000 Patients Treated with Canagliflozin for 3.7 years Benefit 6 MACE events prevented - 5 MIs prevented 11 fewer coronary PCI/CABG - 2 fewer hosp. UA UR 1 fewer fatal cancer 11 fewer arthritis - 4 fewer gouty arthritis Canakinumab 150 mg Risk 1 excess fatal infection 1 excess leukopenia 1 excess thrombocytopenia No excess liver toxicity No excess injection site reactions No excess hemorrhage No effect on stroke, CV death or all-cause mortality
15 Evaluation of CANTOS Trial Deep Dive Benefit-risk balance of Canakinumab Robustness of outcomes Lack of low or normal hscrp group Totality of evidence Implications
16 Quantity of Evidence Necessary to Support Effectiveness of Drugs and Biologics: FDA CFR FDC Act 1962 FDA Evidence Guidance for Industry, 1998 FDAMA 115 (1998) Statutory criterion Substantial evidence of effectiveness consisting of adequate and well-controlled investigations, i.e., two separate trials each with p<0.05 (0.025 x = = 0.001) A highly reliable and statistically persuasive (p value <0.001) evidence of an important clinical benefit in a single trial with some other indication of the study s reliability (e.g., multicenter with no center driving the results) One adequate and well-controlled study and confirmatory evidence.
17 Evaluation of CANTOS Trial Robustness of Outcomes from a Regulatory Perspective Regulatory criterion Attribute Pre-specification Superiority for MACE (PEP), MACE+ (key SEP #1), and new-onset T2DM among pre-diabetics (key SEP #2) prespecified for all 3 doses Exploratory analysis for incident & fatal overall cancer (but not lung cancer) prespecified Replication Preservation of Type 1 error (adjustment for multiple comparisons) MACE or MACE+ does not meet statistically persuasive criterion for a single trial result, i.e. P<0.001, thereby ensuring a replication probability of >90% P value for MACE & MACE+ not robust enough ( & ; multiplicity-adjusted a threshold = & , respectively) MACE or MACE+ does not meet the regulatory criterion for a superiority claim based on substantial evidence of effectiveness
18 Study Group Moderating Robustness of Results Bayesian Analysis of MACE in CANTOS OUTCOME EVENT Total + - Ept Evidence 0.85 ( ) Posterior 0.88 (0.77, 1.00) Con Prior (skeptical) 1.00 (0.75, 1.33) Total Canakinumab Control Incidence Rate (100PY) HR 95% CI P (2-tailed) , Minimum Bayes Factor: N Benefit Log OR Harm Prior NP Post NP Weak to moderate evidence that requires independent substantiation in subsequent studies
19 Evaluation of CANTOS Trial Deep Dive Benefit-risk balance of Canakinumab Robustness of outcomes Lack of low or normal hscrp arm Totality of evidence Implications
20 Evaluation of CANTOS Trial Lack of Low or Normal hscrp Arm CANTOS used an enriched population - High-risk post-mi patients with residual inflammatory risk (hscrp>2) Enrolling low or normal hscrp arm would inflate the sample size FDA-approved claim for Rosuvastatin based on JUPITER - Rosuvastatin is indicated in patients with one additional risk factor in addition to the JUPITER criterion based on age and hscrp>2 - JUPITER excluded patients with hscrp<2 HOPE-3 trial (rosuvastatin for primary prevention) - co-pep #1 (MACE): HR of 0.82 (hscrp<2) and 0.77 (hscrp >2) - co-pep #2 (MACE, cardiac arrest, CHF, revascularization): HR of 0.79 (hscrp<2) and 0.78 (hscrp >2) Without including an arm with low or no inflammation (hscrp <2), can one be sure that CANTOS unequivocally validates the inflammatory hypothesis?
21 Evaluation of CANTOS Trial Deep Dive Benefit-risk balance of Canakinumab Robustness of outcomes Lack of low or normal hscrp group Totality of evidence Implications
22 Inflammatory Hypothesis for Atherothrombosis Totality of Evidence Inflammation CANTOS Pro (Canakinumab: anti-il1b)? LoDoCo (Colchicine) Con Lp-PLA2 inhibition (Darapladib; 2 negative trials: STABILITY, SOLID-TIMI 52) Steroids atherogenesis NSAIDs CVD risk Anti-TNF-a agents mortality Validation of the inflammatory hypothesis implies that targeting of molecules involved in inflammation reduces CV risk
23 Evaluation of CANTOS Trial Deep Dive Benefit-risk balance of Canakinumab Robustness of outcomes Lack of low or normal hscrp group Totality of evidence Implications
24 CANTOS: Responder Analysis (On-Rx hscrp < vs >2) Confirmed MACE by 3 Month hscrp Cumulative Incidence Confirmed MACE by 3 Month hscrp HR (95% CI) P Placebo On Treatment hscrp: >=2.0 mg/l On Treatment hscrp: <2.0 mg/l 1.0 (ref) (ref) 0.95 (0.84,1.09) (0.66,0.85) < hscrp >2mg/L hscrp <2mg/L No. at risk: Follow-up (years) Placebo Canakinumab: hscrp >= 2.0 mg/l hscrp < 2.0 mg/l Ridker PM et al. Lancet 2017; AHA 2017
25 CANTOS Sensitivity Analysis (MACE) Alternative Thresholds for On-treatment hscrp On-treatment hscrp Threshold hscrp < or > clinical cutpoint (2 mg/l) hscrp < or > median (1.8 mg/l) hscrp > or < 50% reduction hscrp > or < Median % (58%) reduction HR (adjusted) 95% CI P HR (adjusted) 95% CI P HR (adjusted) 95% CI P HR (adjusted) 95% CI P Placebo Canakinumab On-treatment hscrp above threshold Canakinumab On-treatment hscrp below threshold < < HRs adjusted for age, gender, smoking, HTN, diabetes, BMI, baseline hscrp, Baseline LDLC Binary response according to clinical cutpoint or median change, but not 50% or median % Ridker PM et al. Lancet 2017; AHA 2017
26 CANTOS Responder Analysis (hscrp < 2 vs >2) Impact on CV Outcomes Clinical Outcome MACE MACE+ CV death All-cause mortality HR (adjusted) 95% CI P HR (adjusted) 95% CI P HR (adjusted) 95% CI P HR (adjusted) 95% CI P Placebo Canakinumab hscrp > 2mg/L (N = 2868) Canakinumab hscrp < 2 mg/l (N = 3484) < < < HRs adjusted for age, gender, smoking, HTN, diabetes, BMI, baseline hscrp, Baseline LDLC Binary response according to clinical cutpoint for all outcomes Ridker PM et al. Lancet 2017; AHA 2017
27 CANTOS Responder Analysis (hscrp < 2 vs >2) Impact of Canakinumab Dose on MACE Canakinumab dose 50 mg SC q 3 months 150 mg SC q 3 months 300 mg SC q 3 months HR (adjusted) 95% CI P HR (adjusted) 95% CI P HR (adjusted) 95% CI P Placebo Canakinumab hscrp > 2mg/L (N = 2868) Canakinumab hscrp < 2 mg/l (N = 3484) The proportions of those treated who achieved hscrp levels < 2 mg/l were 44%, 55%, and 65% in the 50mg, 150mg, and 300mg canakinumab groups, respectively HRs adjusted for age, gender, smoking, HTN, diabetes, BMI, baseline hscrp, Baseline LDLC Binary response according to clinical cutpoint for all 3 doses Ridker PM et al. Lancet 2017; AHA 2017
28 CANTOS Responder Analysis (hscrp < 2 vs >2) Impact on Fatal Infection Clinical Outcome Fatal Infection Incidence rate (per 100 person years) Placebo Canakinumab hscrp > 2mg/L (N = 2868) Canakinumab hscrp < 2 mg/l (N = 3484) FDA WARNINGS AND PRECAUTIONS Interleukin-1 blockade may interfere with immune response to infections. Treatment with medications that work through inhibition of IL-1 has been associated with an increased risk of serious infections How does one explain lack of increase in incident fatal infection while observing greater CV risk reduction with greater IL-1b blockade? Ridker PM et al. Lancet 2017; AHA 2017
29 CANTOS Responder Analysis Limitations that Challenge Interpretation Known Cardiovascular Disease LDL 150 mg/dl hscrp 7.0 mg/l High Intensity Statin Residual Inflammatory Risk LDL 70 mg/dl hscrp 3.0 mg/l Residual Inflammatory Risk LDL 70 mg/dl hscrp 6.0 mg/l Canakinumab 150mg SC hscrp 1.8 mg/l (3 month) D = 1.2mg/L or <50% hscrp 2.8 mg/l (3 month) D = 3.2mg/L or >50% Which patient is a responder and should be a candidate for treatment?
30 CANTOS Responder Analysis (hscrp 3m) Limitations that Challenge Interpretation Patients not randomized to treat-to-target strategy Observational dataset, vulnerable to residual confounding that cannot be overcome by multivariable adjustment Individuals most likely to achieve targets are those who started out with lower baseline values Patients achieving > median (58%) percentage reduction in hscrp versus not (a definition less influenced by baseline hscrp), both groups benefited with substantial overlap in 95% Cis (20% vs 14% RRR) Post-randomization variable ( improper subgroup) Not reliable for regulatory or clinical-decision making
31 Does CANTOS Provide the Elusive Validation of the Inflammatory Hypothesis? The Verdict is in. No! Modest effect size which barely met multiplicity-adjusted P value for significance PEP driven by nonfatal outcomes (MI, revascularization) Vulnerable to missing data (1 or 2 excess events would overturn significance) Not consistent with the FDA statutory criterion of substantial evidence Evidence not strong enough to overcome reasonable degree of skepticism Reverse dose response for CV death (HR 0.80, 0.88 & 0.93 for 50, 150 & 300 mg) Lack of low/normal hscrp arm precludes drawing firm conclusions
32 Does CANTOS Provide the Elusive Validation of the Inflammatory Hypothesis? The Verdict is in. No! Cancer outcomes exploratory and susceptible to false positive error Blockade of innate immunity would be expected to impair tumor surveillance, thereby potentially cancer risk (anti-tnf-a lymphoma; rilonacept malignancy) No affect on COPD incidence, a known risk factor for lung cancer, with canakinumab or MEDI8968, a human anti-interleukin-1 receptor MAb Is reduced cancer risk related to anti-inflammatory effect or inhibition of tumor invasiveness & metastasis mediated by MMP-2 or to a play of chance? Totality of evidence not consistent with the inflammatory hypothesis Prohibitive cost-effectiveness CANTOS did move the needle forward for the inflammatory hypothesis, but not beyond a reasonable doubt!
33 CVOTs Addressing the Inflammatory Hypothesis of Atherothrombosis Trial Type Blind Power (1-b) MDD (d) Cohort Time period CIRT (N=7,000) Methotrexate vs Placebo Superiority DB 90%-95% (514 events) HR 0.75 Post-MI + T2DM or metabolic syndrome LoDoCo2 (N=4,230) Colchicine vs Placebo Superiority DB 90% (331 events) HR 0.70 Stable CAD COLCOT (N=4,500) Colchicine vs Placebo Superiority DB 90% (301 events) NR Post-MI <30d These trials are likely have a greater impact on the inflammatory hypothesis given the safety, tolerability, & affordability of methotrexate and colchicine
34 Extraordinary claims require extraordinary proof Marcello Truzzi
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10,061 39 Countries April 2011 - June 2017
More informationReducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
New York City Cardiovascular Symposium December 10, 2017 Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Paul M Ridker, MD, MPH
More informationInflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationTherapeutic Implications of Vascular Inflammation: The Cardiovascular Inflammation Reduction Trials
Therapeutic Implications of Vascular Inflammation: The Cardiovascular Inflammation Reduction Trials ESC Munich August 25, 2012 Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationStudy 2 ( ) Pivotal Phase 3 Study Top-Line Results. October 29, 2018
Study 2 (1002-047) Pivotal Phase 3 Study Top-Line Results October 29, 2018 Safe Harbor Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements
More informationInflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD
Inflammation, the Inflammasome and CAD Do Cardiologists need to know this? Jacques Genest MD Cardiovascular Research Laboratories Research Institute of the McGill University Health Center Disclosure J.
More informationDo Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus
Do Women Benefit From Statins for Primary Prevention?: Controversy, Challenges and Consensus C. Noel Bairey Merz MD, FACC, FAHA Professor and Women s Guild Endowed Chair Director, Barbra Streisand Women
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationWorkshop. Todd Anderson MD / Jacques Genest MD
Workshop Todd Anderson MD / Jacques Genest MD Game-Changing Trials 2017 FOURIER Evolocumab n=27,564 HR 0.80 CANTOS Canakinumab n=10,061 HR 0.85 COMPASS Rivaroxaban + ASA n=27,395 HR 0.76 Key Secondary
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationCARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD for the CARES Investigators Calhoun Cardiology Center University
More informationTreatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center
Treatment of Cardiovascular Risk Factors Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center Disclosures: None Objectives What do risk factors tell us What to check and when Does treatment
More informationBeyond LDL-Cholesterol
Biomarkers for Risk Stratification Beyond LDL-Cholesterol Athanasios J.Manolis Director Cardioilogy Dep, Asklepeion Hospital, Athens, Greece Adj. Professor of Medicine, Emory University Atlanta, USA Adj.
More informationExpert Meeting on Large Simple Trials (LST s)
Expert Meeting on Large Simple Trials (LST s) Clinical Trials Transformation Initiative Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin JUPITER Johannes
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationCARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)
CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD, for the CARES Investigators Calhoun Cardiology Center University
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationINFLAMMATION &THROMBOSIS INSIGHTS FROM CANTOS TRIAL AHMED NADA, FSCAI ALMOSTAKBAL HOSPITAL, JEDDAH SAUDI ARABIA
INFLAMMATION &THROMBOSIS INSIGHTS FROM CANTOS TRIAL AHMED NADA, FSCAI ALMOSTAKBAL HOSPITAL, JEDDAH SAUDI ARABIA Introduction - Two or three decades ago, many experts predicted that the modification of
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationPreventing Cardiovascular Disease With Lipid Management: Matching Therapy to Risk
PREVENTING CARDIOVASCULAR DISEASE WITH LIPID MANAGEMENT : MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict
More informationNew Insights into the Biology of Atherosclerosis and Primary Prevention: Controversy and Consensus in the JUPITER Trial
Fundacion Fernandez-CruzXXVIII Leccion Memorial New Insights into the Biology of Atherosclerosis and Primary Prevention: Controversy and Consensus in the JUPITER Trial Paul M Ridker, MD, MPH Eugene Braunwald
More informationDoes High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
More informationSubodh Verma, MD PhD FRCSC
CIRT and CANTOS Targeting g Inflammation at in Atherosclerosis e s Subodh Verma, MD PhD FRCSC Cardiac Surgeon, St. Michael s Hospital Associate Professor, Surgery & Pharmacology Canada Research Chair in
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationLDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice Nault, Robert P. Giugliano, Anthony C. Keech, Armando
More informationROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret
ROLE OF INFLAMMATION IN HYPERTENSION Dr Barasa FA Physician Cardiologist Eldoret Outline Inflammation in CVDs the evidence Basic Science in Cardiovascular inflammation: The Main players Inflammation as
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationTYP 2 DIABETES. Marc Donath
TYP 2 DIABETES Marc Donath Treatment of Typ 2 Diabetes GLP-1 Anti-IL-1β Insulin sulfonylureas Metformin UCP-1 IL-1β Sport SGLT2i Bariatric surgery Cardiomyocytes Control Glucose Dyntar et al. Diabetes
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More informationProspective Natural-History Study of Coronary Atherosclerosis
Introduction Review of literature from April 2010 to present Concentrated on clinical studies Categories: Atherosclerosis, Lipids, Diabetes and CVD Risk Medical Therapy Statins really could there be anything
More informationSTABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators
STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationUpdate Diabetes Therapie. Marc Y Donath
Update Diabetes Therapie Marc Y Donath Recent CV outcome studies in Diabetes N Engl J Med. 2015 373:2117-28 (Empa-Reg outcome study) N Engl J Med. 2016 June 13 (LEADER trial) N Engl J Med. 2017 June 12
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationExperiences with interim trial monitoring, particularly with early stopped trials
Experiences with interim trial monitoring, particularly with early stopped trials 1 Robert J Glynn, ScD Divisions of Preventive Medicine and Pharmacoepidemiology & Pharmacoeconomics, Brigham & Women s
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationNew Strategies for Lowering LDL - Are They Really Worth It?
New Strategies for Lowering LDL - Are They Really Worth It? Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of CV Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director,
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationThe ACCELERATE Trial
The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,
More informationCRP for the Clinician
CRP for the Clinician J. C. Kaski, D.Sc., M.D., D.M (Hons), F.E.S.C., F.R.C.P., F.A.C.C. F.A.H.A Professor of Cardiovascular Science Head, Cardiovascular Sciences Research Centre St George s, University
More informationDisclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?
Disclosures JUPITER: The final frontier in statin utilization or an idea from outer space? Kathy E. Komperda, PharmD, BCPS Midwestern University Chicago College of Pharmacy kkompe@midwestern.edu 4/25/09
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationInflammation, rheumatoid arthritis and cardiovascular disease
Inflammation, rheumatoid arthritis and cardiovascular disease Yvette Meißner, Pharmacoepidemiology, German Rheumatism Research Centre www. chronische-entzuendung.org Outline I. Cardiovascular disease II.
More informationLa prevenzione secondaria dopo sindrome coronarica acuta. Aldo Pietro Maggioni Centro Studi ANMCO Firenze
La prevenzione secondaria dopo sindrome coronarica acuta Aldo Pietro Maggioni Centro Studi ANMCO Firenze Trial and community-based assessments of in-hospital (A) and 30-day (B) mortality relative to age
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationRegulatory Hurdles for Drug Approvals
Regulatory Hurdles for Drug Approvals William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research 25 min Conflicts CPC Clinical Research
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationPreventing coronary artery disease: Cholesterol or inflammation?
Preventing coronary artery disease: Cholesterol or inflammation? Alexis Baass MD, MSc, FRCPC, DABCL, FNLA Medical Biochemist and Lipidologist MUHC Clinical Researcher and Lipidologist IRCM Disclaimers
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationWelcome! Mark May 14, Sat!
Welcome! Mark May 14, Sat! Do We Have All Answers with Statins In Treating Patients with Hyperlipidemia? Kwang Kon Koh, MD, PhD, FACC, FAHA Cardiology, Gil Heart Center, Gachon Medical School, Incheon,
More informationANCHOR Study Results Overview
TM ANCHOR Study Results Overview April 18, 2010 Nasdaq: AMRN www.amarincorp.com 1 Forward Looking Statement This presentation contains forward looking statements, including those relating to the Company
More informationThe Clinical Debates
The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More informationsurtout qui n est PAS à risque?
3*25 min et surtout qui n est PAS à risque? 2018 ESC/ESH Hypertension Guidelines 2018 ESC-ESH Guidelines for the Management of Arterial Hypertension 28 th ESH Meeting on Hypertension and Cardiovascular
More informationEvaluation of C-reactive protein prior to and on-treatment as a predictor of benefit
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin. A cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm Peter S Sever,
More informationControversies in Preventative Cardiology
Controversies in Preventative Cardiology Francisco Lopez-Jimenez, M.D., M.Sc, FACC, FAHA Professor of Medicine, Mayo Medical School Chair, Division of Preventive Cardiology Co-Director, Artificial Intelligence
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationInitial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment
Initial Phase 3 Studies Results for Rilonacept in the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapy and the Treatment of Patients in the Midst of an Acute Gout Attack Investor
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationMacrovascular Disease in Diabetes
Macrovascular Disease in Diabetes William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research Conflicts CPC Clinical Research (University-based
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationSanger Heart & Vascular Institute Symposium 2015
Sanger Heart & Vascular Institute Symposium 2015 Cardiovascular Update For Primary Care Physicians William E. Downey, MD FACC FSCAI Medical Director, Interventional Cardiology Sanger Heart & Vascular Institute
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationThe 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories
The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories Cardiac biomarkers in atherosclerosis Najma Asadi MD-APCP Ross and Colleagues in 1973: Response to Injury
More information2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice
2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine
More informationAmerican Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida
The 21 st Century Paradigm Shift: Prevention Rather Than Intervention for the Treatment of Stable CHD The Economic Burden of Cardiovascular Diseases Basil Margolis MD, FACC, FRCP Director, Preventive Cardiology
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationThe earlier BP control the better cardiovascular outcome. Jin Oh Na Cardiovascular center Korea University Medical College
The earlier BP control the better cardiovascular outcome Jin Oh Na Cardiovascular center Korea University Medical College Index Introduction HOPE-3 Trial Sprint Study Summary Each 2 mmhg decrease in SBP
More informationLODOCO Colchocine Research. Mark Nidorf Chairs: Craig Cheetham, Paul Camp
LODOCO Colchocine Research Mark Nidorf Chairs: Craig Cheetham, Paul Camp Colchicine for 2 o Prevention of Cardiovascular Disease LoDoCo2 - An Australian-Dutch Collaboration Atherosclerosis is the Major
More informationCharacterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER
Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER Stephen D Wiviott, Robert P Giugliano, David A Morrow, Gaetano M De Ferrari, Basil S Lewis, Kurt Huber, Julia
More informationRecent Advances & Emerging Data in the Treatment of Hypertriglyceridemia. Michael Miller, MD, FACC, FAHA, FNLA
Recent Advances & Emerging Data in the Treatment of Hypertriglyceridemia Michael Miller, MD, FACC, FAHA, FNLA Professor of Medicine, Epidemiology & Public Health University of Maryland School of Medicine
More informationShould we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationUmbrella study design in patients with Hereditary Periodic Fevers, an orphan autoimmune disease. Karine Lheritier 15 June 2016 PSI Immunology meeting
Umbrella study design in patients with Hereditary Periodic Fevers, an orphan autoimmune disease Karine Lheritier 15 June 2016 PSI Immunology meeting Outline Hereditary Periodic Fevers Canakinumab Study
More informationHYPERCHOLESTEROLEMIA
UPDATES ON HYPERCHOLESTEROLEMIA WITH EMPHASIS ON PCSK9 INHIBITORS July, 2018 Chicago by Ernesto L. Chua, MD, FACC, FACP, FPCP Board Certified in Internal Medicine Board Certified in Cardiology COL, USAF,
More informationIs it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany
Is it ever too late for cardiovascular prevention and rehabilitation? Prof. Dr. Helmut Gohlke Herz-Zentrum Bad Krozingen, Germany The demographic issue Life expectancy is increasing Patients are getting
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More information